Joincare(SH:600380)2016-04-24 16:00Financial Performance - Net profit attributable to shareholders decreased by 10.72% to CNY 159,155,048.20 year-on-year[9] - Operating revenue rose by 11.28% to CNY 2,355,335,131.69 compared to the same period last year[9] - Basic earnings per share decreased by 10.67% to CNY 0.1030[9] - Total operating revenue for the period reached ¥2,355,335,131.69, an increase of 11.27% compared to ¥2,116,591,711.88 in the previous period[40] - Net profit for the period was ¥301,551,578.87, representing a 4.06% increase from ¥289,373,768.42 in the previous period[40] - The total comprehensive income for the period was ¥297,058,606.70, down from ¥313,853,652.46 in the previous period[41] - The company experienced a decrease in other comprehensive income after tax, totaling -¥4,492,972.17 compared to ¥24,479,884.04 in the previous period[40] Cash Flow - Net cash flow from operating activities increased by 49.55% to CNY 268,421,196.40 year-on-year[9] - Cash flow from operating activities generated ¥268,421,196.40, an increase of 49.52% compared to ¥179,481,337.52 in the previous period[43] - The net cash flow from operating activities for Q1 2016 was -64,086,923.17 RMB, a significant decline compared to 50,874,540.68 RMB in the same period last year[46] - Total cash inflow from operating activities was 360,338,130.68 RMB, while cash outflow was 424,425,053.85 RMB, resulting in a net cash outflow of 64,086,923.17 RMB[46] - The company reported a net cash flow from investing activities of -201,198,093.33 RMB, compared to -2,856,931.13 RMB in the previous year[46] - Cash inflow from financing activities was 10,000,000.00 RMB, while cash outflow was -9,671.50 RMB, leading to a net cash flow from financing activities of 10,009,671.50 RMB[47] Assets and Liabilities - Total assets increased by 2.44% to CNY 14,131,855,804.97 compared to the end of the previous year[9] - The company's cash and cash equivalents stood at CNY 2,280,456,952.16, slightly up from CNY 2,271,090,578.72 at the start of the year, indicating a marginal increase of about 0.4%[33] - Total liabilities increased to CNY 6,540,980,841.92 from CNY 6,488,460,678.42, reflecting a growth of approximately 0.81%[34] - Current assets decreased to CNY 2,407,845,969.69 from CNY 2,579,042,939.69, a decline of about 6.63%[36] - The company has a goodwill amounting to CNY 614,468,698.73, unchanged from the previous period, indicating stability in this asset category[33] Shareholder Information - The total number of shareholders reached 125,795 at the end of the reporting period[11] - The largest shareholder, Shenzhen Baiye Yuan Investment Co., Ltd., holds 46.78% of the shares[11] Investments and Subsidiaries - Long-term equity investments increased by 64.91% to ¥567,339,273.03, mainly from equity investments by subsidiary Tiancheng Industrial[16] - The company is in the process of listing its subsidiary, Lizhu Pharmaceutical Group Co., Ltd., on the Hong Kong Stock Exchange, which is referred to as the B to H project[22] - The company has established a priority right for Lizhu Group regarding any business opportunities that may compete with restricted businesses[23] Commitments and Regulations - The company has committed to not distributing profits to shareholders and to postpone major external investments and acquisitions if it anticipates difficulties in repaying bond principal and interest[25] - The company has assured that the report contains no false records, misleading statements, or significant omissions, taking full responsibility for the accuracy and completeness of the information[28]